New combo targets genetic weakness in advanced cancers
NCT ID NCT07417501
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial is testing whether a combination of lenvatinib (a targeted drug) and a PD-1 inhibitor (immunotherapy) can shrink or stop advanced solid tumors that have a specific genetic change called 11q13 amplification. About 60 adults with various cancers like esophageal, head and neck, breast, lung, or liver cancer will take lenvatinib daily and receive the immunotherapy every 3 weeks. Researchers will track tumor response, side effects, and survival to see if this approach is effective and safe.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- lenvatinib plus a PD-1 inhibitor (a type of immunotherapy)
- What this could lead to
- If it works, this could point toward a new treatment option for people with advanced cancers that have a specific genetic change (11q13 amplification).
- What could go wrong
- This is an early phase 2 trial with only 60 participants, so results may not apply to everyone. The combination may cause side effects or not work for many tumor types.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMORS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tongji Hospital
Wuhan, Hubei, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Spinal injection of dual immunotherapy plus chemotherapy targets cancer spread to brain lining
- Lab-Made immune protein takes on advanced cancers in first human test
- Blood test may let cancer patients take safe breaks from immunotherapy
- Engineered immune cells take on Hard-to-Treat cancers
- Experimental cell therapy takes aim at Hard-to-Treat cancers
- Could simple Over-the-Counter drugs supercharge cancer immunotherapy?